



June 19, 2014

COR/2014/06-09

- **Director Enforcement**
Securities & Exchange Commission of Pakistan
NIC Building
Jinnah Avenue, Blue Area
Islamabad.
- **The General Manager**
Lahore Stock Exchange Limited
Stock Exchange Building
19 Khayaban-E-Aiwan-E-Iqbal
Kashmir Road
Lahore.
- **The General Manager**
Karachi Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.
- **The General Manager**
Islamabad Stock Exchange Limited
ISE Tower, 55-B
Jinnah Avenue, Blue Area
Islamabad.

Dear Sir(s),

MATERIAL INFORMATION

In accordance with the Section-15(D) of the Securities and Exchange Ordinance, 1969 and the clause-(xx) of the Listing Regulation-35 of Karachi Stock Exchange and clause-(xxiii) of Listing Regulation-35 of Lahore Stock Exchange & Islamabad Stock Exchange under the Code of Corporate Governance, we are pleased to convey the following information:

Ferozsons Laboratories Limited has entered into agreement with Gilead Sciences to be its exclusive branded medicines business partner for Pakistan.

Under the agreement, Ferozsons will market and distribute in Pakistan certain Gilead medications:

- Sovaldi® for the treatment of chronic hepatitis C as a component of a combination antiviral treatment.
- HIV therapies Viread® (tenofovir disoproxil fumarate), Truvada® (emtricitabine/tenofovir disoproxil fumarate) and the newer single tablet regimen Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
- Viread® for its indication as a treatment for chronic hepatitis B virus (HBV) infection.

Osman Khalid Waheed, President of Ferozsons Laboratories Limited, commented, "This agreement is a very important milestone for the company, but more significantly it also marks a paradigm shift in the treatment landscape for diseases like Hepatitis C, which affects over 10 million people in the country. We look forward to bringing these new innovations to patients in Pakistan."

Stribild and Sovaldi are pending registration in Pakistan. The registration application for Sovaldi was submitted in May 2014, with the request for an accelerated review on the basis of medical need.

In addition to distributing branded Gilead medicines, Ferozsons will manage regulatory and pharmacovigilance activities (such as adverse event reporting), as well as broader medical education initiatives.

Page 1 of 2



Head Office/Biotech Factory:
5-K.M- Sunder Raiwind Road
Raiwind Lahore, Pakistan.
Office phones: +92 42 36826700
+92 42 32104001-3
Fax: +92 42 36826701-2
Factory phones: +92 505 5052135
Fax: +92 42 36026791

Registered Office:
197 A
The Mall Rawalpindi, 46000
Pakistan.
Phones: +92-51-5562155-67
Fax: +92-51-5584195
+92-51-5566881

Pharma Factory:
P.O. Ferozsons
Amangarh Nowshera. (KPK)
Pakistan.
Phones: +92-923-614295
+92-923-610159
Fax: +92-923-611302
+92-923-611547

Sales Office: Lahore
43-At Noor Building,
Bank Square, The Mall,
Lahore, Pakistan.
Phones: +92-42 37358194
Fax: +92 42-37313680

Sales Office: Karachi
House No.9, Mughal Cooperative
Society Shahwali-e-Faisal Karachi,
Pakistan.
Phones: +92-21 34386852
Fax: +92 21 34386754

email: info@ferozsons-labs.comwww.ferozsons-labs.com